Tirzepatide: Evidence, Safety, and FDA Status

What Is Tirzepatide?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist used in FDA-approved prescription products including Mounjaro and Zepbound. Zepbound is approved for chronic weight management and, in adults with obesity, moderate-to-severe obstructive sleep apnea; Mounjaro is used for type 2 diabetes.

Mechanism of Action

• Dual receptor agonism: activates both GIP and GLP-1 receptors rather than GLP-1 alone.
• Glucose-dependent insulin secretion: supports insulin release when glucose is elevated.
• Appetite and energy intake: central and gastrointestinal signaling contributes to lower energy intake and weight loss.
• Mechanistic uncertainty remains: the clinical effect of the combined molecule is well demonstrated, but the exact contribution of GIP signaling to each downstream outcome is still an active research question.

What the Evidence Shows

• Obesity: in SURMOUNT-1, mean body-weight change at 72 weeks was about −20.9% with the 15 mg dose under the treatment-regimen estimand, versus −3.1% with placebo.
• Type 2 diabetes: the SURPASS program demonstrated substantial glycemic and weight effects; SURPASS-2 directly compared tirzepatide with semaglutide 1 mg in people with type 2 diabetes.
• Direct obesity comparison: SURMOUNT-5, published in 2025, found greater mean weight reduction with maximum tolerated tirzepatide than with maximum tolerated semaglutide after 72 weeks in adults with obesity without diabetes.
• Obstructive sleep apnea: FDA approved Zepbound in December 2024 for moderate-to-severe OSA in adults with obesity, alongside reduced-calorie diet and increased physical activity.
• Cardiovascular outcomes: SURPASS-CVOT is no longer an ongoing evidence gap. Published results found tirzepatide noninferior to dulaglutide for cardiovascular death, myocardial infarction, or stroke in people with type 2 diabetes and atherosclerotic cardiovascular disease; superiority over dulaglutide was not established for the primary endpoint.

Evidence quality: strong for studied indications and populations. Direct trials now support several claims that previously rested on indirect or emerging data, but those results should still be described with their actual comparator, population, dose, and endpoint.

FDA & Compounding Status (August 2026)

FDA determined the tirzepatide injection shortage was resolved in December 2024. Shortage-related enforcement discretion that had allowed broader production of essentially copies has ended.

• Section 503A pharmacies and physicians: patient-specific compounding can qualify for statutory exemptions when all 503A conditions are met, including restrictions against regularly or in inordinate amounts making products that are essentially copies of commercially available drugs.
• Section 503B outsourcing facilities: FDA states that tirzepatide is not currently on the 503B bulks list and is not on the drug-shortage list, so outsourcing facilities cannot rely on shortage status as a basis for routine bulk compounding.
• 503B bulks-list proposal: FDA proposed on April 30, 2026 to exclude tirzepatide, semaglutide, and liraglutide from the 503B bulks list after finding no clinical need for outsourcing-facility bulk compounding. FDA described this as a proposal and said public comments would be considered before a final determination.

Practical reading: the rules are more specific than saying all compounded tirzepatide simply requires a generic physician letter of “clinical necessity.” The statutory pathway, whether a product is essentially a copy, the source of the bulk drug substance, and the applicable 503A or 503B conditions matter.

Safety Considerations

• Common adverse effects: nausea, diarrhea, vomiting, constipation, and other gastrointestinal symptoms are common, particularly during dose escalation.
• Important warnings: FDA labeling addresses pancreatitis, gallbladder disease, hypoglycemia in relevant drug combinations, kidney injury related to volume depletion, and pulmonary aspiration during general anesthesia or deep sedation.
• Boxed warning: thyroid C-cell tumors occurred in rats; use is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
• Pregnancy: weight-loss treatment is not appropriate during pregnancy; product-specific labeling should guide reproductive questions.
• Compounded products: efficacy and safety data for FDA-approved tirzepatide products do not establish equivalent identity, concentration accuracy, sterility, delivery performance, or quality for compounded preparations.

Bottom Line

Tirzepatide has strong randomized evidence for diabetes and obesity, direct obesity comparison data against semaglutide, an FDA-approved OSA indication for Zepbound, and a completed cardiovascular outcomes trial. In 2026, the main wording trap is regulatory: shortage resolution, 503A patient-specific compounding, 503B bulk-compounding restrictions, and FDA approval are different concepts and should not be collapsed into one blanket statement about compounded access.